Raymond James Financial Services Advisors Inc. lowered its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Free Report) by 46.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,103 shares of the biopharmaceutical company’s stock after selling 34,204 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Sangamo Therapeutics were worth $52,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its holdings in Sangamo Therapeutics by 278.8% during the second quarter. Allspring Global Investments Holdings LLC now owns 46,408 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 34,157 shares during the period. Diversified Trust Co bought a new position in shares of Sangamo Therapeutics during the 2nd quarter valued at about $33,000. Golden State Equity Partners bought a new position in shares of Sangamo Therapeutics during the 1st quarter valued at about $239,000. JPMorgan Chase & Co. lifted its holdings in shares of Sangamo Therapeutics by 0.8% during the 1st quarter. JPMorgan Chase & Co. now owns 1,574,172 shares of the biopharmaceutical company’s stock valued at $2,771,000 after purchasing an additional 11,863 shares in the last quarter. Finally, Hudson Bay Capital Management LP lifted its holdings in shares of Sangamo Therapeutics by 3.7% during the 1st quarter. Hudson Bay Capital Management LP now owns 1,200,000 shares of the biopharmaceutical company’s stock valued at $2,112,000 after purchasing an additional 42,400 shares in the last quarter. Institutional investors and hedge funds own 59.81% of the company’s stock.
In related news, major shareholder Biogen Inc. sold 6,000,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $0.50, for a total transaction of $3,000,000.00. Following the transaction, the insider now directly owns 17,652,466 shares of the company’s stock, valued at approximately $8,826,233. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.00% of the company’s stock.
Wall Street Analyst Weigh In
Sangamo Therapeutics Trading Down 4.9 %
NASDAQ SGMO opened at $0.42 on Wednesday. The company has a market cap of $74.49 million, a PE ratio of -0.29 and a beta of 1.12. Sangamo Therapeutics, Inc. has a 12 month low of $0.42 and a 12 month high of $4.22. The stock has a 50 day moving average of $0.68 and a 200-day moving average of $1.05.
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $6.84 million during the quarter, compared to analyst estimates of $22.33 million. Sangamo Therapeutics had a negative net margin of 123.88% and a negative return on equity of 61.40%. As a group, sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
- Five stocks we like better than Sangamo Therapeutics
- Manufacturing Stocks Investing
- GSK is a remedy for the winter investment blahs
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- After blowout earnings, Integer may be headed to new highs
- Stock Market Sectors: What Are They and How Many Are There?
- Banking and trucking: Is the economy rolling toward troubles?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.